XML 44 R34.htm IDEA: XBRL DOCUMENT
v3.22.1

Fair Value of Assets and Liabilities - Assets and Liabilities (Details) $ in Thousands | 3 Months Ended |  |
--- | --- | --- | ---
Mar. 31, 2022 USD ($) property shares | Mar. 31, 2021 USD ($) | Dec. 31, 2021 USD ($) | Mar. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis |  |  |  |
Losses on equity securities, net | $ (8,553) | $ (8,339) |  |
Corporate Joint Venture | Seaport Innovation LLC |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis |  |  |  |
Equity method investment ownership percentage | 20.00% |  | 20.00% | 55.00%
Holding period | 10 years |  |  |
Corporate Joint Venture | Seaport Innovation LLC | Measurement Input, Discount Rate |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis |  |  |  |
Measurement input | 0.0558 |  |  |
Corporate Joint Venture | Seaport Innovation LLC | Measurement Input, Market Capitalization Rate |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis |  |  |  |
Measurement input | 0.0525 |  |  |
Corporate Joint Venture | Medical Office and Life Science Properties |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis |  |  |  |
Equity method investment ownership percentage | 20.00% |  |  |
Holding period | 10 years |  |  |
Number Of owned properties | property | 10 |  |  |
Corporate Joint Venture | Medical Office and Life Science Properties | Measurement Input, Discount Rate | Minimum |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis |  |  |  |
Measurement input | 0.0567 |  |  |
Corporate Joint Venture | Medical Office and Life Science Properties | Measurement Input, Discount Rate | Maximum |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis |  |  |  |
Measurement input | 0.0893 |  |  |
Corporate Joint Venture | Medical Office and Life Science Properties | Measurement Input, Market Capitalization Rate | Minimum |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis |  |  |  |
Measurement input | 0.0475 |  |  |
Corporate Joint Venture | Medical Office and Life Science Properties | Measurement Input, Market Capitalization Rate | Maximum |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis |  |  |  |
Measurement input | 0.0600 |  |  |
Recurring | Carrying Amount | AlerisLife Inc |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis |  |  |  |
Investments in affiliates, fair value | $ 22,987 |  |  |
Recurring | Level 1 | Carrying Amount | AlerisLife Inc |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis |  |  |  |
Investments in affiliates, fair value | $ 22,987 |  | $ 31,540 |
Equity securities investment (in shares) | shares | 10,691,658 |  |  |
Recurring | Level 1 | Estimated Fair Value | AlerisLife Inc |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis |  |  |  |
Investments in affiliates, fair value | $ 22,987 |  | 31,540 |
Recurring | Level 3 | Joint Venture | Carrying Amount | Life Science Property |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis |  |  |  |
Investments in affiliates, fair value |  |  | 215,127 |
Recurring | Level 3 | Joint Venture | Carrying Amount | Medical Office and Life Science Properties |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis |  |  |  |
Investments in affiliates, fair value |  |  | 0 |
Recurring | Level 3 | Joint Venture | Estimated Fair Value | Life Science Property |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis |  |  |  |
Investments in affiliates, fair value | 216,416 |  | 215,127 |
Recurring | Level 3 | Joint Venture | Estimated Fair Value | Medical Office and Life Science Properties |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis |  |  |  |
Investments in affiliates, fair value | $ 50,325 |  | $ 0 |

X
- Definition Equity Securities, FV-NI, Holding Period + References No definition available. + Details
Name: | dhc_EquitySecuritiesFVNIHoldingPeriod
Namespace Prefix: | dhc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Owned Properties + References No definition available. + Details
Name: | dhc_NumberOfOwnedProperties
Namespace Prefix: | dhc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258 + Details
Name: | us-gaap_EquitySecuritiesFvNiMeasurementInput
Namespace Prefix: | us-gaap_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Balance held at close of period in number of shares. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section 50 -Paragraph 6 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -URI http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010 + Details
Name: | us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Fair value portion of investments in an entity not consolidated. Includes, but is not limited to, investments in an entity that is affiliated with the reporting entity by means of direct or indirect ownership, an entity in which the reporting entity shares control of the entity with another party or group, an entity which the company has significant influence, but does not have control and subsidiaries that are not required to be consolidated and are accounted for using the equity or cost method. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258 + Details
Name: | us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI). + References No definition available. + Details
Name: | us-gaap_MarketableSecuritiesGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dhc_SeaportInnovationLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=dhc_MeasurementInputMarketCapitalizationRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dhc_MedicalOfficeAndLifeSciencePropertiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dhc_AlerisLifeIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dhc_JointVentureMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dhc_LifeSciencePropertyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |